comparemela.com

Latest Breaking News On - Kumaon mandal vikas nigam ltd - Page 1 : comparemela.com

Krishnadatt Awasthy vs State Of M P on 4 April, 2024

Krishnadatt Awasthy vs State Of M P on 4 April, 2024
indiankanoon.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiankanoon.org Daily Mail and Mail on Sunday newspapers.

Govt gets multiple preliminary bids for strategic sale of IMPCL: DIPAM

Currently, the Indian government holds a 98.11% stake in IMPCL, which is a prominent manufacturer of 656 classical ayurvedic, 332 unani, and 71 proprietary ayurvedic medicines, catering to a wide range of diseases. The company supplies ayurveda and unani medicines to all states under the National Ayush Mission (NAM) as well as 6,000 Jan Aushadhi Kendras centers.

disinvestment: Govt invites EoIs for IMPCL strategic sale

The Indian government has invited bids for the strategic sale of Indian Medicines Pharmaceutical Corporation Ltd (IMPCL), in which it holds a 98.11% stake. The remaining 1.89% is held by Kumaon Mandal Vikas Nigam Ltd (KMVNL). The government plans to disinvest its entire stake in IMPCL through strategic disinvestment with a transfer of management control. IMPCL is a profit-making organization that manufactures ayurvedic and unani medicines and supplies them to all states under the National Ayush Mission.

India invites bids for privatisation of Indian Medicines Pharmaceutical

India has invited bids for the privatisation of Indian Medicines Pharmaceutical Corporation, the government said on Thursday. It plans to sells its 98.1% stake in the company that.

Govt invites Expression of Interest from bidders for IMPCL strategic sale

Govt invites Expression of Interest from bidders for IMPCL strategic sale
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.